Updates from ASH in Later Line Multiple Myeloma Management
Updates from ASH in Later Line Multiple Myeloma Management
MyCancerHaven
Experts Discuss How to Choose Between CAR-Ts and Bispecifics in Myeloma
FEATURING
Ravi Vij,
Nitya Nathwani
- 174 views
- May 2, 2024
- 2
Moffitt Cancer Center
New FDA Approvals of CAR-Ts Earlier in Myeloma: What You Need to Know
FEATURING
Doris Hansen
- 261 views
- April 15, 2024
- 1
Indy Hematology Review
Emerging and Cellular Therapeutic Options for MM: Understanding Your Immune Effector Therapeutic Options
FEATURING
Saad Usmani
- 174 views
- April 18, 2024
- 1
UChicago Medicine
Car T-Cells and Bispecifics in Myeloma: A Case for Moving Them Early
FEATURING
Noopur Raje
- 142 views
- March 18, 2024
- 1
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
2024 Updates on the Role of Immunotherapy for MM
FEATURING
Adam D. Cohen
- 172 views
- March 1, 2024
- 3
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
How I Treat R/R MM With CAR-T and Bispecific Antibodies
FEATURING
Claudio Cerchione
- 127 views
- February 15, 2024
5th SOHO Italy Annual Conference
SOHO Italy 2023: New Insights and Opportunities for Lenalidomide Refractory Patients - Future Perspectives
FEATURING
Jesús San-Miguel
- 90 views
- November 28, 2023
- 1
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Inflammatory Biomarkers and Outcomes in MM Patients After CAR T-Cell Therapy"
FEATURING
Darren Pan
- 60 views
- December 22, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "KarMMa-3 Trial - Ide-Cel vs. Standard Regimens in Patients With Triple-Class-Exposed R/R MM"
FEATURING
Krina Patel
- 80 views
- February 12, 2024
- 1
Scripps MD Anderson Cancer Center
Current Summary of the Multiple Myeloma Treatment Landscape
FEATURING
Rebecca Lu
- 589 views
- November 6, 2023
- 5
Icahn School of Medicine at Mount Sinai
Adverse Effects of CAR-T: Myeloma Edition
FEATURING
Sridevi Rajeeve
- 248 views
- May 24, 2023
- 1